RxDoctor Payments Data

Mary Morris, APRN

Adult Health · Oklahoma City, OKNPI 1699150649

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,058 of the $1,182 with a category attached, or 89.5%. It is spread thinly across 11 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations.

$1,182in general payments, 2019–2025

Across 33 payments — averaging $35.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$267
  • Takeda Pharmaceuticals U.S.A., Inc.$258
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$254
  • Johnson & Johnson$135
  • Ardelyx, Inc.$117
  • AbbVie$37
  • plus $114 from 5 others

What the payments were for

  • Food & beverage$1,05890%
  • Education$12410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,182 in reported general payments places this provider in the 60th percentile of 117 adult health providers in Oklahoma.

See all adult health providers in Oklahoma

Medicare billing

Part B allowed, 2024
$38,340
Medicare patients
248
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir13$304,492
SucraidSacrosidase14$224,612
OcalivaObeticholic Acid13$120,154
CreonLipase/Protease/Amylase19$57,590
LinzessLinaclotide43$40,426
TrulancePlecanatide23$24,333
MovantikNaloxegol Oxalate34$23,947
Lubiprostone75$9,154
Dexlansoprazole DrDexlansoprazole31$8,584
Ursodiol41$8,495
Budesonide DrBudesonide22$4,044
Omeprazole164$3,124
Famotidine117$2,339
Pantoprazole Sodium179$2,088
Colestipol Hcl22$1,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa$16$304,49213 claims
AbbVieCreon, Linzess$37$98,01662 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$254$24,33323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 117 adult health providers in Oklahoma.

Other adult health in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →